Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma

Richard W Joseph, Ryan J. Sullivan, Robyn Harrell, Katherine Stemke-Hale, David Panka, George Manoukian, Andrew Percy, Roland L. Bassett, Chaan S. Ng, Laszlo Radvanyi, Patrick Hwu, Michael B. Atkins, Michael A. Davies

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

The purpose of this study is to identify clinical and molecular characteristics of melanoma patients that predict response to high-dose interleukin-2 (HD IL-2) to improve patient selection for this approved but toxic therapy. We reviewed the records of 208 patients with unresectable stage III/IV melanoma treated with HD IL-2 at the University of Texas M.D. Anderson Cancer Center (n=100) and the Beth Israel Deaconess Medical Center (n=108) between 2003 and 2009. The BRAF and NRAS mutation status of the tumors was determined for patients with available tissue samples and the mutation status and clinical characteristics were compared with clinical outcomes. Pretreatment serum lactate dehydrogenase levels were available for most patients (n=194). Tissue was available for mutational analysis on a subset of patients (n=103) and the prevalence of mutations was as follows: BRAF 60%, NRAS 15%, WT/WT 25%. In the subset of patients for which mutational analysis was available, there was a significant difference in the response rate based on the mutation status: NRAS 47%, BRAF 23%, and WT/WT 12% (P=0.05). Patients with NRAS mutations had nonstatistically longer overall survival (5.3 vs. 2.4 y, P=0.30) and progression-free survival (214 vs. 70 d, P=0.13). Patients with an elevated lactate dehydrogenase level had a decreased progression-free survival (46 vs. 76 d, P<0.0001), decreased overall survival (0.56 vs. 1.97 y, P<0.0001), and trended toward a decreased response rate (7% vs. 21%, P=0.08). NRAS mutational status is a new candidate biomarkers for selecting patients with melanoma for HD IL-2 treatment.

Original languageEnglish (US)
Pages (from-to)66-72
Number of pages7
JournalJournal of Immunotherapy
Volume35
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Fingerprint

Interleukin-2
Melanoma
Mutation
L-Lactate Dehydrogenase
Disease-Free Survival
Survival
Poisons
Israel
Patient Selection
Neoplasms
Biomarkers
Therapeutics
Serum

Keywords

  • BRAF
  • IL-2
  • LDH
  • melanoma
  • NRAS

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Cancer Research
  • Pharmacology

Cite this

Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. / Joseph, Richard W; Sullivan, Ryan J.; Harrell, Robyn; Stemke-Hale, Katherine; Panka, David; Manoukian, George; Percy, Andrew; Bassett, Roland L.; Ng, Chaan S.; Radvanyi, Laszlo; Hwu, Patrick; Atkins, Michael B.; Davies, Michael A.

In: Journal of Immunotherapy, Vol. 35, No. 1, 01.2012, p. 66-72.

Research output: Contribution to journalArticle

Joseph, RW, Sullivan, RJ, Harrell, R, Stemke-Hale, K, Panka, D, Manoukian, G, Percy, A, Bassett, RL, Ng, CS, Radvanyi, L, Hwu, P, Atkins, MB & Davies, MA 2012, 'Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma', Journal of Immunotherapy, vol. 35, no. 1, pp. 66-72. https://doi.org/10.1097/CJI.0b013e3182372636
Joseph, Richard W ; Sullivan, Ryan J. ; Harrell, Robyn ; Stemke-Hale, Katherine ; Panka, David ; Manoukian, George ; Percy, Andrew ; Bassett, Roland L. ; Ng, Chaan S. ; Radvanyi, Laszlo ; Hwu, Patrick ; Atkins, Michael B. ; Davies, Michael A. / Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. In: Journal of Immunotherapy. 2012 ; Vol. 35, No. 1. pp. 66-72.
@article{394d28f655a74c028c263a3e8cdc874e,
title = "Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma",
abstract = "The purpose of this study is to identify clinical and molecular characteristics of melanoma patients that predict response to high-dose interleukin-2 (HD IL-2) to improve patient selection for this approved but toxic therapy. We reviewed the records of 208 patients with unresectable stage III/IV melanoma treated with HD IL-2 at the University of Texas M.D. Anderson Cancer Center (n=100) and the Beth Israel Deaconess Medical Center (n=108) between 2003 and 2009. The BRAF and NRAS mutation status of the tumors was determined for patients with available tissue samples and the mutation status and clinical characteristics were compared with clinical outcomes. Pretreatment serum lactate dehydrogenase levels were available for most patients (n=194). Tissue was available for mutational analysis on a subset of patients (n=103) and the prevalence of mutations was as follows: BRAF 60{\%}, NRAS 15{\%}, WT/WT 25{\%}. In the subset of patients for which mutational analysis was available, there was a significant difference in the response rate based on the mutation status: NRAS 47{\%}, BRAF 23{\%}, and WT/WT 12{\%} (P=0.05). Patients with NRAS mutations had nonstatistically longer overall survival (5.3 vs. 2.4 y, P=0.30) and progression-free survival (214 vs. 70 d, P=0.13). Patients with an elevated lactate dehydrogenase level had a decreased progression-free survival (46 vs. 76 d, P<0.0001), decreased overall survival (0.56 vs. 1.97 y, P<0.0001), and trended toward a decreased response rate (7{\%} vs. 21{\%}, P=0.08). NRAS mutational status is a new candidate biomarkers for selecting patients with melanoma for HD IL-2 treatment.",
keywords = "BRAF, IL-2, LDH, melanoma, NRAS",
author = "Joseph, {Richard W} and Sullivan, {Ryan J.} and Robyn Harrell and Katherine Stemke-Hale and David Panka and George Manoukian and Andrew Percy and Bassett, {Roland L.} and Ng, {Chaan S.} and Laszlo Radvanyi and Patrick Hwu and Atkins, {Michael B.} and Davies, {Michael A.}",
year = "2012",
month = "1",
doi = "10.1097/CJI.0b013e3182372636",
language = "English (US)",
volume = "35",
pages = "66--72",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma

AU - Joseph, Richard W

AU - Sullivan, Ryan J.

AU - Harrell, Robyn

AU - Stemke-Hale, Katherine

AU - Panka, David

AU - Manoukian, George

AU - Percy, Andrew

AU - Bassett, Roland L.

AU - Ng, Chaan S.

AU - Radvanyi, Laszlo

AU - Hwu, Patrick

AU - Atkins, Michael B.

AU - Davies, Michael A.

PY - 2012/1

Y1 - 2012/1

N2 - The purpose of this study is to identify clinical and molecular characteristics of melanoma patients that predict response to high-dose interleukin-2 (HD IL-2) to improve patient selection for this approved but toxic therapy. We reviewed the records of 208 patients with unresectable stage III/IV melanoma treated with HD IL-2 at the University of Texas M.D. Anderson Cancer Center (n=100) and the Beth Israel Deaconess Medical Center (n=108) between 2003 and 2009. The BRAF and NRAS mutation status of the tumors was determined for patients with available tissue samples and the mutation status and clinical characteristics were compared with clinical outcomes. Pretreatment serum lactate dehydrogenase levels were available for most patients (n=194). Tissue was available for mutational analysis on a subset of patients (n=103) and the prevalence of mutations was as follows: BRAF 60%, NRAS 15%, WT/WT 25%. In the subset of patients for which mutational analysis was available, there was a significant difference in the response rate based on the mutation status: NRAS 47%, BRAF 23%, and WT/WT 12% (P=0.05). Patients with NRAS mutations had nonstatistically longer overall survival (5.3 vs. 2.4 y, P=0.30) and progression-free survival (214 vs. 70 d, P=0.13). Patients with an elevated lactate dehydrogenase level had a decreased progression-free survival (46 vs. 76 d, P<0.0001), decreased overall survival (0.56 vs. 1.97 y, P<0.0001), and trended toward a decreased response rate (7% vs. 21%, P=0.08). NRAS mutational status is a new candidate biomarkers for selecting patients with melanoma for HD IL-2 treatment.

AB - The purpose of this study is to identify clinical and molecular characteristics of melanoma patients that predict response to high-dose interleukin-2 (HD IL-2) to improve patient selection for this approved but toxic therapy. We reviewed the records of 208 patients with unresectable stage III/IV melanoma treated with HD IL-2 at the University of Texas M.D. Anderson Cancer Center (n=100) and the Beth Israel Deaconess Medical Center (n=108) between 2003 and 2009. The BRAF and NRAS mutation status of the tumors was determined for patients with available tissue samples and the mutation status and clinical characteristics were compared with clinical outcomes. Pretreatment serum lactate dehydrogenase levels were available for most patients (n=194). Tissue was available for mutational analysis on a subset of patients (n=103) and the prevalence of mutations was as follows: BRAF 60%, NRAS 15%, WT/WT 25%. In the subset of patients for which mutational analysis was available, there was a significant difference in the response rate based on the mutation status: NRAS 47%, BRAF 23%, and WT/WT 12% (P=0.05). Patients with NRAS mutations had nonstatistically longer overall survival (5.3 vs. 2.4 y, P=0.30) and progression-free survival (214 vs. 70 d, P=0.13). Patients with an elevated lactate dehydrogenase level had a decreased progression-free survival (46 vs. 76 d, P<0.0001), decreased overall survival (0.56 vs. 1.97 y, P<0.0001), and trended toward a decreased response rate (7% vs. 21%, P=0.08). NRAS mutational status is a new candidate biomarkers for selecting patients with melanoma for HD IL-2 treatment.

KW - BRAF

KW - IL-2

KW - LDH

KW - melanoma

KW - NRAS

UR - http://www.scopus.com/inward/record.url?scp=84155171313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84155171313&partnerID=8YFLogxK

U2 - 10.1097/CJI.0b013e3182372636

DO - 10.1097/CJI.0b013e3182372636

M3 - Article

VL - 35

SP - 66

EP - 72

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 1

ER -